Midway Capital Research & Management Invests $3.81 Million in Stryker Corporation $SYK

Midway Capital Research & Management acquired a new stake in shares of Stryker Corporation (NYSE:SYK) during the fourth quarter, Holdings Channel.com reports. The fund acquired 10,851 shares of the medical technology company’s stock, valued at approximately $3,814,000. Stryker accounts for approximately 3.7% of Midway Capital Research & Management’s portfolio, making the stock its 8th largest holding.

Several other hedge funds also recently bought and sold shares of SYK. Sankala Group LLC bought a new position in shares of Stryker during the 4th quarter valued at $26,000. Godfrey Financial Associates Inc. bought a new position in shares of Stryker in the fourth quarter worth about $26,000. United Financial Planning Group LLC acquired a new position in shares of Stryker during the third quarter worth approximately $27,000. Atlas Capital Advisors Inc. acquired a new position in Stryker during the 4th quarter valued at $27,000. Finally, DJE Kapital AG acquired a new position in shares of Stryker during the fourth quarter valued at about $28,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.45, for a total transaction of $992,075.00. Following the sale, the vice president owned 177 shares of the company’s stock, valued at approximately $50,170.65. This represents a 95.19% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is owned by company insiders.

Stryker Stock Up 0.3%

Shares of NYSE:SYK opened at $308.62 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87. The company has a 50 day moving average price of $313.81 and a two-hundred day moving average price of $341.71. The company has a market capitalization of $118.31 billion, a PE ratio of 35.72, a PEG ratio of 1.97 and a beta of 0.78.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same period in the previous year, the company posted $2.84 earnings per share. Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts forecast that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio is 40.74%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Weiss Ratings cut Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Jefferies Financial Group reiterated a “buy” rating and set a $465.00 price target on shares of Stryker in a research note on Wednesday, March 4th. Canaccord Genuity Group decreased their target price on shares of Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Truist Financial reiterated a “hold” rating and set a $330.00 price objective (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Finally, Robert W. Baird set a $385.00 price objective on shares of Stryker in a report on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $395.33.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.